INTRODUCTION AND OBJECTIVES: MicroRNA 21 (miR-21)
is overexpressed in virtually all types of cancers including prostate cancer (PCa). We have previously reported that the androgen receptor (AR) induces miR-21 expression, and that elevated miR-21 is sufficient to drive PCa growth and castration resistance. However, the role of miR-21 in PCa initiation and progression has not been fully elucidated. To determine if the absence of miR-21 inhibits or delays prostate cancer incidence or progression, we crossed miR-21 KO mice with Hi-Myc mice. In this study, we identify that loss of miR-21 delays Myc-driven prostate cancer progression in the Hi-Myc transgenic mouse model. METHODS: miR-21 KO mice were backcrossed to FVB mice to generation F10. Resulting miR-21 WT or KO FVB progeny were crossed with Hi-Myc mice to generate Hi-Myc/miR-21 WT or KO mice. Prostates were harvested at 4 weeks (n¼10), 3 months (n¼10), 5 months (n¼58), 6 months (n¼25), 8 months (n¼20), 9 months (n¼19) and 13 months (n¼15) of age and prostate weight, histology and protein expression levels were quantified. Castration was performed at 8m and prostates were subsequently harvested at 9m or 13m to examine the effect of castration.
RESULTS: Hi-Myc/miR-21 KO mice demonstrated a marked reduction in adenocarcinoma when compared to Hi-Myc/miR-21 WT mice at 5m (Fig. 1A, 1B ). This is apparent in the reduced weight of effected prostate lobes of Hi-Myc/miR-21 KO versus WT mice at 8m (Fig. 1C) . Protein levels of established miR-21 target genes, PDCD4 and PTEN, were up-regulated in the prostates of Hi-Myc/miR-21 KO mice (Fig. 1D) . However, miR-21 KO did not affect prostatic intraepithelial neoplasia (PIN) development ( Fig. 2A) or cancer progression after castration (Fig. 2B, 2C) .
CONCLUSIONS: Our results demonstrate that miR-21 contributes to Myc-driven prostate cancer progression and that endogenous miR-21 suppresses prostatic PDCD4 and PTEN protein expression levels. Therefore, targeting of miR-21 or its downstream target genes may be useful for cancer prevention or cancer therapy. 
MP29-08 HSD3B1 PREFERENTIALLY UTILIZES PREGNENOLONE TO PROMOTE RESISTANCE TO ANTI-ANDROGENS IN PROSTATE CANCER
Cameron Armstrong*, Chengfei Liu, Wei Lou, Christopher Evans, Allen Gao, Sacramento, CA INTRODUCTION AND OBJECTIVES: Most prostate cancer (PCa) patients receiving enzalutamide (Enza) or abiraterone (Abi) develop drug resistance within 24 months of exposure. This creates a need to better understand the underlying causes of anti-androgen resistance so that improved treatment methods can be developed. Previous studies demonstrate that uncontrolled intraprostatic androgen synthesis promotes Enza and Abi resistance. HSD3B1 is a key enzyme contributing to androgen synthesis and its expression is associated with PCa progression. The aim of this study is to determine the contribution of HSD3B1 to Enza and Abi resistance in PCa.
METHODS: Enza resistant (C4-2B MDVR) and Abi resistant (C4-2B AbiR) C4-2B PCa cells were generated by chronically exposing parental C4-2B cells to increasing Enza or Abi concentrations for >12 months and maintained in 20 mM Enza or 10 mM Abi. Differences in gene expression between parental and anti-androgen resistant cells was determined by microarray, RNA-seq, and rtPCR. HSD3B1 expression was knocked down in C4-2B MDVR and C4-2B AbiR cells using shRNA and cell number was determined in media containing FBS, charcoal dextran stripped FBS (CD-FBS), or CD-FBS supplemented with 100 nM pregnenolone (P5), 100 nM DHEA, or 10 nM DHT in the presence and absence of 20 mM Enza. PSA secretion was determined by ELISA and PSA-luciferase activity was measured by reporter assay.
RESULTS: HSD3B1 expression is higher in C4-2B MDVR and C4-2B AbiR cells compared to parental C4-2B cells. This correlates to increased intracrine androgens in C4-2B MDVR cells. Knockdown of e368 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 
